Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jorgen Jensen who wrote (951)	2/17/2004 10:13:48 AM
From: tuck	Read Replies (1) \| Respond to of 975

>>BOSTON--(BUSINESS WIRE)--Feb. 17, 2004-- Boston Life Sciences, Inc. (NASDAQ: BLSI - News) announced that the Company has received the FDA's response to its latest special protocol assessment (SPA) submission for Altropane® for the indication of differentiating Parkinsonian from non-Parkinsonian syndromes in patients with tremors. The FDA requested further modification to the statistical presentation section of the protocol relating to statistical methodologies. The Agency also provided statistical guidance regarding the circumstances under which this single Phase III study would be sufficient to achieve approvability for this indication, and the Company is further seeking clarification on this point. The Company believes that these requested changes do not pose a significant obstacle to obtaining the SPA Agreement and has already made the requested modifications to the statistical plan in order to satisfy the conditions for an SPA Agreement. "The requested changes to the statistical plan have been made, and a conference call with the FDA to resolve any remaining ambiguities has been scheduled," stated Marc Lanser, MD, President of BLSI. "Based on the feedback from the Agency, we currently believe that an additional full protocol submission will not be necessary in order to secure an SPA Agreement with the Agency, but no absolute assurances can be made until final agreement is reached with the Agency. In any case, we will continue to respond positively and quickly to requested modifications to the SPA protocol, since we believe that concluding a formal SPA agreement is important to the timely success of Altropane and to the Company," added Dr. Lanser. << snip Waiting for Godot. . . . Cheers, Tuck

To: Jorgen Jensen who wrote (951)	4/1/2004 12:49:07 PM
From: tuck	Read Replies (2) \| Respond to of 975

OK, looks like a reasonable trial design. It would be nice to know how long it will take. Perhaps they'll give us a hint when they actually initiate it. I wouldn't think that, at 25 centers, enrollment would take that long. >>BOSTON--(BUSINESS WIRE)--April 1, 2004-- Boston Life Sciences, Inc. (NASDAQ: BLSI - News) announced that the Company has reached a binding agreement from the FDA regarding the Company's protocol design for a new Phase III clinical trial of ALTROPANE®, a radioimaging agent under development by Boston Life Sciences for the differentiation of Parkinsonian tremors from tremors due to other, non-Parkinsonian causes. This written Agreement represents the culmination of a number of teleconferences, meetings and protocol revisions occurring over an eight-month period in which the Company and FDA refined the study design for this single, pivotal trial. The resulting agreement binds the FDA and the Company to the precise design and statistical plan outlined in the approved protocol. The Company believes that, if successful, i.e. that the endpoints are met and no significant safety concerns or protocol deviations occur, this Phase III trial will provide the basis for an NDA submission and ultimate approvability of ALTROPANE. This Phase III study will enroll at least 500 subjects (250 with Parkinsonian tremor and 250 with non-Parkinsonian tremor) in up to 25 centers in the U.S.; most of which are university-based. Subjects suspected of having tremor will be referred to a neurology clinic for enrollment in the study. Upon diagnosis of Parkinsonian or non-Parkinsonian tremor by the subjects' internist or general practitioner, the subjects will be administered ALTROPANE and a SPECT image will be obtained. Subsequent to SPECT scanning, the subject will be evaluated and diagnosed by a Movement Disorders Specialist (MDS). Throughout the two-day period of evaluation, the subjects will be monitored for safety. Upon completion of the study, various analyses of the data will be conducted. Primary analyses will comprise assessments of the sensitivity and specificity of the ALTROPANE SPECT procedure versus the diagnosis of an internist or general practitioner. The primary endpoint of the study is to demonstrate statistically significant superiority of the ALTROPANE scan diagnosis compared to that of an internist or general practitioner, using the diagnosis of a Movement Disorder Specialist (MDS) as the "gold standard". Because we have elected to pursue this single, large Phase III trial, we have powered the trial to achieve a high level of significance. "We are extremely pleased to have obtained this binding agreement from the FDA on our proposed protocol. The FDA allowed us to revise our protocol in February without incurring the delays in having to submit a new SPA filing. The written correspondence that we have received from the FDA expressly states that the agreement we have now reached constitutes 'a binding agreement, as described in the Guidelines for Industry-Special Protocol Assessments.' As a result, the agreement gives us a clear pathway to an NDA filing for this important indication. We hope to initiate this pivotal study shortly," stated Dr. Marc Lanser, President of BLSI.<< snip Cheers, Tuck